Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29676
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMease, Philip J.-
dc.contributor.authorKavanaugh, Arthur-
dc.contributor.authorReimold, Andreas-
dc.contributor.authorTahir, Hasan-
dc.contributor.authorRech, Juergen-
dc.contributor.authorHall, Stephen-
dc.contributor.authorGEUSENS, Piet-
dc.contributor.authorPellet, Pascale-
dc.contributor.authorDelicha, Eumorphia Maria-
dc.contributor.authorPricop, Luminita-
dc.contributor.authorMpofu, Shephard-
dc.date.accessioned2019-10-03T14:16:44Z-
dc.date.available2019-10-03T14:16:44Z-
dc.date.issued2019-
dc.identifier.citationANNALS OF THE RHEUMATIC DISEASES, 78, p. 917-917 (Art N° FRI0451)-
dc.identifier.issn0003-4967-
dc.identifier.urihttp://hdl.handle.net/1942/29676-
dc.language.isoen-
dc.publisherBMJ PUBLISHING GROUP-
dc.subject.otherRheumatology-
dc.titleSecukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: Final 5 year efficacy and safety results from a phase 3 trial-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 12-15, 2019-
local.bibliographicCitation.conferencenameAnnual European Congress of Rheumatology (EULAR)-
local.bibliographicCitation.conferenceplaceMadrid, SPAIN-
dc.identifier.epage917-
dc.identifier.spage917-
dc.identifier.volume78-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Mease, Philip J.] Swedish Med Ctr, Seattle, WA USA. [Mease, Philip J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, Arthur] Univ Calif San Diego, Sch Med, La Jolla, CA USA. [Reimold, Andreas] Dallas VA Med Ctr, Dallas, TX USA. [Reimold, Andreas] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, Hasan] Barts Hlth NHS Trust, London, England. [Rech, Juergen] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Erlangen, Germany. [Hall, Stephen] Monash Univ, Melbourne, Vic, Australia. [Geusens, Piet] Univ Hasselt, Hasselt, Belgium. [Geusens, Piet] Maastricht Univ Hosp, Maastricht, Netherlands. [Pellet, Pascale; Delicha, Eumorphia Maria; Mpofu, Shephard] Novartis Pharma AG, Basel, Switzerland. [Pricop, Luminita] Novartis Pharmaceut, E Hanover, NJ USA.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrFRI0451-
dc.identifier.doi10.1136/annrheumdis-2019-eular.2768-
dc.identifier.isi000472207102496-
item.contributorMease, Philip J.-
item.contributorKavanaugh, Arthur-
item.contributorReimold, Andreas-
item.contributorTahir, Hasan-
item.contributorRech, Juergen-
item.contributorHall, Stephen-
item.contributorGEUSENS, Piet-
item.contributorPellet, Pascale-
item.contributorDelicha, Eumorphia Maria-
item.contributorPricop, Luminita-
item.contributorMpofu, Shephard-
item.fulltextWith Fulltext-
item.accessRightsRestricted Access-
item.fullcitationMease, Philip J.; Kavanaugh, Arthur; Reimold, Andreas; Tahir, Hasan; Rech, Juergen; Hall, Stephen; GEUSENS, Piet; Pellet, Pascale; Delicha, Eumorphia Maria; Pricop, Luminita & Mpofu, Shephard (2019) Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: Final 5 year efficacy and safety results from a phase 3 trial. In: ANNALS OF THE RHEUMATIC DISEASES, 78, p. 917-917 (Art N° FRI0451).-
crisitem.journal.issn0003-4967-
crisitem.journal.eissn1468-2060-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
mease 1.pdf
  Restricted Access		Published version50.18 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.